top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS
The FDA grants orphan drug status to incentivize the development of one of a kind drugs and other medical treatments. This status grants...
Nov 4, 20182 min read
Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:
Ness Ziona, Israel, October 9, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces progress in the Phase 1 / 2a...
Oct 9, 20183 min read
Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem
Ness Ziona Science Park, Israel, October 2, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of...
Oct 2, 20182 min read
Kadimastem and The AFDR Selected to Receive a bi-National Grant
Ness Ziona, Israel, July 2nd 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval of the Australian...
Jul 2, 20182 min read
Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial
Kadimastem chose to upgrade the production rooms, for the treatment of ALS patients in the Phase 1 / 2a clinical trial, and adapt them to...
Jul 1, 20181 min read
Kadimastem was honored with a prize for excellence for the presentation of the company's technology
Between June 20 and 22, 2018, European conference was held for ALS (ENCALS) at Oxford University in England. During the conference, the...
Jun 27, 20181 min read
Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:
Report in English and a Hebrew summary https://maya.tase.co.il/reports/details/1167249/2/0 https://maya.tase.co.il/reports/details/116724...
Jun 13, 20181 min read
Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published
Jun. 6, 2018 by a Prestigious Cell Therapy Scientific Journal Ness Ziona, Israel, 6 June 2018, Israeli biotechnology company Kadimastem...
Jun 6, 20183 min read
Successful Public Offering for Kadimastem
May. 15, 2018 Ness Ziona, Israel, May 15, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the completion of a...
May 15, 20181 min read
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
Apr. 26, 2018 Ness Ziona, Israel, 26 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the enrollment of...
Apr 26, 20182 min read
Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes
Ness Ziona, Israel, 22 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the signing of a memorandum of...
Apr 22, 20183 min read
Successful Rights Offering for Kadimastem; Raised NIS 5.1M
The company's stakeholders invested a substantial sum of NIS 3.8M Ness Ziona, Israel, 13 November 2014, Israeli biotechnology company...
Nov 13, 20141 min read
Kadimastem to Raise up to NIS 10M in Rights Offering
Oct. 14, 2014 The company's stakeholders will invest significant sums in the offering Ness Ziona, Israel, 14 October 2014, Israeli...
Oct 14, 20141 min read
Kadimastem Received Response from FDA:
The Development Process for the Stem Cell-Based Drug for ALS is Expected to be Significantly Shortened Oct. 7, 2014 The company reported...
Oct 7, 20141 min read
Kadimastem Approached the FDA Regarding Its ALS Treatment
Oct. 6, 2014 The company recently reported positive results in its first pre-clinical trial for the treatment of ALS. Ness Ziona, Israel,...
Oct 6, 20142 min read
Kadimastem to collaborate with Merck Serono to advance efforts in neurodegenerative diseases
Aug. 3, 2014 Nes Ziona, Science Park, 3 August, 2014, Israeli biotechnology company Kadimastem (TASE: KDST) reports that it has signed a...
Aug 3, 20142 min read
Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS
Jul. 20, 2014 Nes Ziona Science Park, 20 July 2014, Israeli biotechnology company Kadimastem (TASE: KDST) reports that it has received...
Jun 20, 20142 min read
Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS
Jun. 18, 2014 Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS)When brain supporting...
Jun 18, 20143 min read
Kadimastem Receives Approval for U.S. Patent
Jun. 2, 2014 Nes Ziona Science Park, June 2 2014, Kadimastem, which develops stem cells for treatments for serious diseases, has received...
Jun 2, 20142 min read
Leading pharma entrepreneur Avi Meizler believes in Kadimastem!
Mar. 19, 2014 Leading Pharma Entrepreneur Avi Meizler believes in Kadimastem!Investing around 1.7 million shekels in the Company Yossi...
Mar 19, 20142 min read
bottom of page